CD274 and lung cancer: The aim is to evaluate the expression of programmed death ligand 1 (PD‐L1) in patients with non–small cell lung cancer (NSCLC) using quantitative perfusion parameters based on dynamic contrast‐enhanced magnetic resonance imaging (DCE‐MRI).